Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049411 | 0.79 | — | — | |
| SCHEMBL6049296 | 0.75 | KMT2A (0.46) | MEN1KMT2AMAPT | |
| SCHEMBL6049279 | 0.75 | — | — | |
| SCHEMBL6049308 | 0.75 | MEN1 (0.46) | LMNAMEN1KMT2AMAPT | |
| SCHEMBL7279723 | 0.73 | HPGD (0.61) | TAAR1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6049275 | 0.72 | GAA (0.53) | GAAMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6049319 | 0.72 | KMT2A (0.47) | ALOX12MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6049228 | 0.69 | PPARG (0.46) | LMNAALOX12ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7282871 | 0.69 | SLC2A1 (0.67) | TAAR1KDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL6049253 | 0.68 | PPARA (0.48) | GAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264480-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | SUH YOUNG G | 2006-11-23 | — | — | US | disclosed |
| US-20030203944-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264480-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TRPV5 | LMNA 4260/4885TAAR1 409/4885CYP1A2 1440/4885 |
| US-20030203944-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TRPV5 | LMNA 4260/4885TAAR1 409/4885CYP1A2 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.